Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8933320 | 1.00 | RARB (0.39) | RARBSPHK1CYP3A4CYP2C9GAA | |
| SCHEMBL8933037 | 1.00 | RARB (0.39) | RARBSPHK1CYP3A4CYP2C9GAA | |
| SCHEMBL8933255 | 1.00 | RARB (0.39) | RARBSPHK1CYP3A4CYP2C9GAA | |
| SCHEMBL8933172 | 1.00 | RARB (0.39) | RARBSPHK1CYP3A4CYP2C9GAA | |
| SCHEMBL8933120 | 1.00 | RARB (0.39) | RARBSPHK1CYP3A4CYP2C9GAA | |
| SCHEMBL8933277 | 1.00 | RARB (0.39) | RARBSPHK1CYP3A4CYP2C9GAA | |
| SCHEMBL8933021 | 1.00 | RARB (0.39) | RARBSPHK1CYP3A4CYP2C9GAA | |
| SCHEMBL8932971 | 1.00 | RARB (0.39) | RARBSPHK1CYP3A4CYP2C9GAA | |
| SCHEMBL8933020 | 1.00 | RARB (0.39) | RARBSPHK1CYP3A4CYP2C9GAA | |
| SCHEMBL8933266 | 1.00 | RARB (0.39) | RARBSPHK1CYP3A4CYP2C9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, HCN3, FZD7 | RARB 3042/4885SPHK1 2159/4885CYP3A4 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.